Shares of Australian oncology-focused biotech Novogen (ASX: NRT) rose 11.1% to A$0.09 today, after the company revealed it has entered into a worldwide licensing agreement with Genentech, a subsidiary of Swiss pharma giant Roche (ROG: SIX), to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway.
The lead indication for GDC-0084 is glioblastoma multiforme (GBM), which is the most aggressive form of brain cancer, accounting for around 15% of primary brain tumours. Median overall survival is considered to be about 12-15 months from the time of diagnosis.
Will pay an initial $5 million to Genentech
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze